# Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients

> **NCT01197287** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 76 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** QAK423A
- **DRUG:** QAK423A
- **DRUG:** QAK423A

## Key facts

- **NCT ID:** NCT01197287
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2005-02
- **Final completion:** —
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2010-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01197287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01197287, "Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01197287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*